Skip to main content

Table 1 Primer and probe lists.

From: Optimisation of region-specific reference gene selection and relative gene expression analysis methods for pre-clinical trials of Huntington's disease

GENE

FORWARD PRIMER

REVERSE PRIMER

PROBE (5' FAM, 3' TAMRA)

Arl6ip2

TTTGGAATGAAGTGTTTGTGATTGA

GGCACCCTGGGTATCCATTA

AGACCTAATGGAACAAAAGTGGCTGTGCTG

Actb

GCTTCTTTGCAGCTCCTTCGT

CCAGCGCAGCGATATCG

CGGTCCACACCCGCCACCAG

Bdnf I

GCAAAGCCGAACTTCTCACAT

GCAACCGAAGTATGAAATAACCATAG

TTCCACCAGGTGAGAAGAGTGATGACCAT

Bdnf IIa

ACAGAGCCAGCGGATTTGTC

GCAACCGAAGTATGAAATAACCATAG

TTCCACCAGGTGAGAAGAGTGATGACCAT

Bdnf IIb

AGTTGGCTTCCTAGCGGTGTAG

GCAACCGAAGTATGAAATAACCATAG

TTCCACCAGGTGAGAAGAGTGATGACCAT

Bdnf IIc

TGCAACTCTTTATCACCAGGATCTA

GCAACCGAAGTATGAAATAACCATAG

TTCCACCAGGTGAGAAGAGTGATGACCAT

Bdnf III

GGGCCGGATGCTTCCTT

GCAACCGAAGTATGAAATAACCATAG

TTCCACCAGGTGAGAAGAGTGATGACCAT

Bdnf IV

CTGCCTTGATGTTTACTTTGACAAG

GCAACCGAAGTATGAAATAACCATAG

TTCCACCAGGTGAGAAGAGTGATGACCAT

Bdnf V

GGGATCCGAGAGCTTTGTG

GCAACCGAAGTATGAAATAACCATAG

TTCCACCAGGTGAGAAGAGTGATGACCAT

Bdnf VI

TCCTGAGGAAGTGAAAGTTTTGACT

GCAACCGAAGTATGAAATAACCATAG

TTCCACCAGGTGAGAAGAGTGATGACCAT

Bdnf VII

GATTGCTGAAAATGGTGTCGTAAA

GCAACCGAAGTATGAAATAACCATAG

TTCCACCAGGTGAGAAGAGTGATGACCAT

Bdnf VIII

CTGGATGCCGCAAACATGTC

CTGCCGCTGTGACCCACTC

TCACACACGCTCAGCTCCCCACGG

Cnr1

CACAAGCACGCCAATAACACA

ACAGTGCTCTTGATGCAGCTTTC

CCAGCATGCACAGGGCCGC

Darpp32

CCCGACAGGTGGAGATGATC

GCTGCACAGCTTTCAGTGATG

CTGCCATGCTTTTCCGGGTCTCAGA

Drd2

ACACCACTCAAGGGCAACTGT

GGCGGGCAGCATCCA

CCCTGAGGACATGAAACTCTGCACCG

Grin1

TCAGTGTGTGAGGACCTCATCTCT

GAGTGAAGTGGTCGTTGGGAGTA

CAGGTCTACGCTATCCTAGTTAGTCACCCGCC

Hdh

CTCAGAAGTGCAGGCCTTACCT

GATTCCTCCGGTCTTTTGCTT

TGAATCTTCTTCCATGCCTGACCCGA

HD (transgenic)

GCTGCACCGACCGTGAGT

CGCAGGCTGCAGGGTTAC

CAGCTCCCTGTCCCGGCGG

Igfbp5

AAGGATTCTACAAGAGAAAGCAGTGTAA

ACTTGTCCACACACCAGCAGAT

TCCCGTGGCCGCAAACGTG

Kcnk2

GACTACGTGGCAGGTGGATCA

GCCAGCCCAACGAGGAT

AATATCTGGACTTCTACAAGCCTGTGGTGTGGT

Nab2

GGGAGGGCAAACAGCTTAGC

AGTGTTGTCCCTCATGCAGAACT

ACCATCAACGAGGCTGCTGCC

Nr4a2

ATTTCCTCGAAAACTCCAATAACTCT

TGAGGCGAGGACCCATACTG

CTGAAGCCATGCCTTGTGTTCAGGC

Pcp4

CTGAGCTGTTCTGTGGGACCTA

CGCTCCGGCACTTTGTCT

CTGCGGAGTCAGGCCAACATGA

Penk1

ATGCAGCTACCGCCTGGTT

GCAGCTGTCCTTCACATTCCA

AGGCGACATCAATTTCCTGGCGTG

Polr2a

GGTGCTGAGTGAGAAGGATGTAGA

ATGCCCAGTACCGTGAAGATCT

TGCGCACCACGTCCAATGATATTGTG

Psme1

TGATGACCAACCTTCACACCAA

TCACCCCTCTCGGAGAAGTACT'

CTGGAAGGCTTCCACACGCAGATCTCC

Sez6

TGTGCCAGTGGGACCTAAGC

TCACAGACATATTGCACAGTTGCT

CATGCCAGAGAGTGACATCTTGCCA

Tbr2

CAAAGGCTTCCGGGACAAC

GGGAGATGGAGTTAACCTGTCATTT

CGATTCCATGTACACGGCTTCAG

UchL1

GGTACCATCGGGTTGATCCA

AACTGTTTCAGGACGGATCCA

AACCAAGACAAGCTGGAATTTGAGGA

Wdr6

GAACAAGCACAAGATGATCAAGGT

GCCTATCGTTGTCAAGCTCACA

TGAGACCAGGTACATGTCTCTTGCTATT

  1. The forward and reverse primer sequences, together with the Taqman probe sequences for each gene routinely used in our laboratory are listed.
  2. KEY: Arl6ip2 (ADP-ribosylation factor-like 6 interacting protein 2); Actb (beta-actin); Bdnf (Brain-derived neurotrophic factor; Roman numerals refer to promoter-specific amplification); Cnr1 (Cannabinoid receptor 1); Darpp32 (Dopamine and cAMP regulated neuronal phosphoprotein, also known as Ppp1r1b, protein phosphatase 1, regulatory subunit 1B); Drd2 (Dopamine D2 receptor); Grin1 (glutamate receptor, ionotropic, NMDA1 {zeta 1}); Hdh (Murine huntington's disease gene homologue); Htt (Human Huntington's disease gene, used to detect human exon 1 transgene); Igfbp5 (insulin-like growth factor binding protein 5 precursor); Kcnk2 (potassium channel, subfamily K, member 2); Nab2 (Ngfi-A binding protein 2); Nr4a2 (nuclear receptor subfamily 4, group A, member 2); Pcp4 (Purkinje cell protein 4); Penk1 (Preproenkephalin); Polr2a (RNA polymerase II {DNA directed} polypeptide A); Psme1 (proteasome activator 28-α subunit); Sez6 (seizure related gene 6); Tbr2 (eomesodermin homolog), Uchl1 (ubiquitin carboxyl-terminal hydrolase L1), Wdr6 (WD repeat domain 6).
Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326